Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma
- 409 Downloads
CD44 is well known to be one of the cancer stem cell markers and is a cell-surface glycoprotein involved in cell–cell interactions, cell adhesion, and cell migration. We investigated the role of CD44 expression in both tumor and non-tumor tissues on recurrence of hepatocellular carcinoma (HCC).
Forty-eight patients with HCC who underwent hepatic resection at our institution were enrolled in this study. CD44 expressions in both tumor and non-tumor tissues were examined using real time reverse transcription-polymerase chain reaction. The patients were divided into two groups: high and low gene-expression group, based on the CD44 expression level. We compared the clinicopathological factors between the high expression and low expression groups in both tumor and non-tumor tissues.
In the tumor tissues, the gene-expression levels of CD44 did not correlate with any clinicopathological parameters. The disease-free survival rate showed no significant difference between the two groups. In non-tumor tissues, although there was no significant relationship between the CD44 expression levels and clinicopathological factors, disease-free survival rate in the CD44 low expression group was significantly better than that in the CD44 high expression group (P < 0.05). In multivariate analysis, the risk factors in tumor recurrence were presence of microscopic portal invasion and high expression level of CD44.
The CD44 expressions in the non-tumor tissues may predict HCC recurrence.
KeywordsHepatocellular carcinoma CD44 Prognostic factor Non-tumor tissue
Reverse transcription-polymerase chain reaction
White blood cell
Indocyanine green retention rate at 15 min
This work was supported in part by Grants-in-Aid for Scientific Research (B) (20390359) and for Scientific Research (C) (22591506), and Grant-in-Aid for Challenging Exploratory Research (22659233 and 22659243), Japan Society for the Promotion of Science. This work was also supported in part by a grant from the Cancer Research Project Cooperated by TAIHO Pharmaceutical Co., LTD., and the University of Tokushima.
Conflict of interest
All authors declare that they have no conflict of interest.